Skip to Main Content
Try STAT+ TODAY
Trending:
The Obesity Revolution
STAT+
Health
Biotech
Subscribe Now To access exclusive content, subscribe to STAT+
View Latest View the latest STAT+ stories
Biotech
STAT+

Arie Belldegrun, building out his new CAR-T startup, pursues senior biotech sell-sider for CFO post

  • Adam Feuerstein

By Adam Feuerstein May 6, 2018

Reprints
ASH19 CAR-T and cancer cell
NIH

Allogene Therapeutics, the new and buzzy CAR-T cancer therapy startup backed by former Kite Pharma CEO Arie Belldegrun, is recruiting veteran Cowen biotech analyst Eric Schmidt to become its new chief financial officer, STAT has learned.

Schmidt confirmed to STAT that he is considering a job offer with Allogene but “no decision has been made” on whether he will accept. Schmidt says he informed his higher-ups at Cowen last week that he was considering a move.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

About the Author Reprints

Adam Feuerstein

Adam Feuerstein

Senior Writer, Biotech

Adam Feuerstein is STAT’s national biotech columnist, reporting on the intersection of biotech and Wall Street. He's also a co-host of "The Readout LOUD" podcast.

Tags

FDA advisory panel recommends conditional approval of Biogen’s drug…
FDA advisory panel recommends conditional approval of Biogen’s drug for rare form of ALS
Researchers devise new strategies to overcome a key CRISPR…
Researchers devise new strategies to overcome a key CRISPR flaw
Flawed herpes testing leads to many false positives —…
Flawed herpes testing leads to many false positives — and needless suffering
Key senators blast Medicare Advantage insurers for ‘exorbitant salaries,’…
Key senators blast Medicare Advantage insurers for ‘exorbitant salaries,’ ‘massive payouts’ to execs
FDA advisory panel recommends conditional approval of Biogen’s drug…
FDA advisory panel recommends conditional approval of Biogen’s drug for rare form of ALS
Drugmakers push back on a clever tactic employers use…
Drugmakers push back on a clever tactic employers use to avoid paying for specialty medicines

Recommended Stories